Penumbra, Inc. (PEN) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Is Penumbra, Inc. stock overvalued or undervalued in 2026?
Penumbra, Inc. (PEN) trades at 80.3× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $121 (-62 %).
Kaplio overview: Penumbra, Inc.
Market cap $13B · 52 weeks $226 – $359 (11 % below the high) · P/E 80.3× · 2027 expected P/E 53.2× · Dividend none · Next earnings February 24, 2027 · expected EPS $1.44 · Closing price, Oct 30 · accounts published Oct 29.
- Valuation: P/E 80.3× (expensive).
- Business: ROIC 8 % (weak).
- Balance sheet: Net debt/EBITDA 0.1× (solid).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
At its sector median (30.4×) $121 (-62 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 3 of 6 pass
- R&D / Revenue 6.4 %, fails.
- ROIC 7.9 %, fails.
- Gross margin 67.1 %, borderline.
- FCF / Net Income 98.5 %, passes, near the threshold.
- Net debt / EBITDA 0.1×, passes.
- P/E vs own 10y history 80.3×, passes.
Against its peers (reference peers) — Penumbra, Inc.: P/E 80.3×; EV/EBITDA 54.6×; ROIC 7.9 %; $12.6B. Edwards Lifesciences Corporation (P/E 52.9×; EV/EBITDA 32.1×; ROIC 10.2 %; $53.0B), Boston Scientific Corporation (P/E 17.8×; EV/EBITDA 13.5×; ROIC 10.5 %; $60.8B), Medtronic Plc (P/E 23.8×; EV/EBITDA 14.7×; ROIC 6.4 %; $123B).
Profitability
| Return on Equity | 10.44% |
| Return on Invested Capital | 7.91% |
| Return on Assets | 7.75% |
| Gross Margin | 67.98% |
| Operating Margin | 12.13% |
| Net Margin | 10.06% |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 5.89 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 20.17 |
Price Performance
| 1 month | +0.44% |
| 3 months | -1.26% |
| Year-to-date | +2.59% |
| 1 year | +40.28% |
| 3 years | +60.87% |
| 5 years | +14.12% |
| 10 years | +443.82% |
Related companies: BSX · ISRG · MMSI · ABT · MDT · EW
Explore sector: Healthcare · Medical - Devices
More sections of PEN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks